Glycosylation Matters More in Non-IgG: Risk Points and Practical QC Strategy Control
The landscape of therapeutic antibodies is rapidly evolving. For decades, the biopharmaceutical industry has heavily relied on the standard Immunoglobulin G (IgG) framework to develop life-saving treatments for oncology, autoimmune diseases, andRead More…